Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Aug 11, 2022 8:32am
182 Views
Post# 34887600

RE:RE:RE:RE:RE:Expectations

RE:RE:RE:RE:RE:Expectations
gudisgood wrote:
longrun86 wrote:

I am focussed mostly on the operating performance this Quarter.

My wish list would be revenue north of $68 million and operating EBITDA greater than $15 million.

Adding to my wish list, I would like an update on the guidance as well as some insight into capital allocation timing.

Hope you are all enjoying the summer and getting in sone quality family time!
 

LR




Seems like you got your first two wishes! :) Happy for you, haha.


Exactly - and then things get a little cloudy ... but expected.
1.  Great revenue increase
2.  Costs going up as we return to the field and they increase R&D activity
3.  Record amortizations of intangibles (or what seems to be record)
4.  Financial assets hurt us unlike the same quarter a year ago - expected
5.  Foriegn exchange turned around this time.

Can see the amortization effect in the large EBITDA number.

Guessing that's the worst of the financial investment hits for a bit - hopefully that's bottomed out with the markets.

More fence sitting - but expected - until operations is the main effect and the obvious growth driver on the numbers.  IMO.

<< Previous
Bullboard Posts
Next >>